[go: up one dir, main page]

AU2014375637A1 - Formula of neuregulin preparation - Google Patents

Formula of neuregulin preparation

Info

Publication number
AU2014375637A1
AU2014375637A1 AU2014375637A AU2014375637A AU2014375637A1 AU 2014375637 A1 AU2014375637 A1 AU 2014375637A1 AU 2014375637 A AU2014375637 A AU 2014375637A AU 2014375637 A AU2014375637 A AU 2014375637A AU 2014375637 A1 AU2014375637 A1 AU 2014375637A1
Authority
AU
Australia
Prior art keywords
neuregulin
formula
preparation
treating
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014375637A
Other languages
English (en)
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53493186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014375637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Publication of AU2014375637A1 publication Critical patent/AU2014375637A1/en
Assigned to ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, CO., LTD. reassignment ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, CO., LTD. Alteration of Name(s) of Applicant(s) under S113 Assignors: ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2014375637A 2014-01-03 2014-12-17 Formula of neuregulin preparation Abandoned AU2014375637A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410002665.6A CN104758922A (zh) 2014-01-03 2014-01-03 纽兰格林制剂的配方
CN201410002665.6 2014-01-03
PCT/CN2014/094073 WO2015101182A1 (zh) 2014-01-03 2014-12-17 纽兰格林制剂的配方

Publications (1)

Publication Number Publication Date
AU2014375637A1 true AU2014375637A1 (en) 2016-07-14

Family

ID=53493186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014375637A Abandoned AU2014375637A1 (en) 2014-01-03 2014-12-17 Formula of neuregulin preparation

Country Status (10)

Country Link
US (3) US10702585B2 (ru)
EP (2) EP3821904B1 (ru)
JP (4) JP6703483B2 (ru)
KR (3) KR102522140B1 (ru)
CN (4) CN104758922A (ru)
AU (1) AU2014375637A1 (ru)
BR (1) BR112016015660A2 (ru)
CA (1) CA2935607A1 (ru)
RU (1) RU2738158C2 (ru)
WO (1) WO2015101182A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
KR102083046B1 (ko) 2012-06-07 2020-02-28 칠드런＇스 하스피틀 로스 앤젤레스 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
US10098834B2 (en) 2013-05-22 2018-10-16 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758922A (zh) * 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EA202092458A1 (ru) 2018-04-11 2021-02-08 Салюбрис Байотерапьютикс, Инк. Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
KR20220066116A (ko) * 2019-09-16 2022-05-23 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 재조합 인간 뉴레귤린 유도체 및 그의 용도
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたｈｍｇｂ１含有溶液
US20230034390A1 (en) * 2019-12-16 2023-02-02 Seagen Inc. High performance liquid chromatography quantification of excipients

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
IL130827A0 (en) 1997-02-10 2001-01-28 Genentech Inc Heregulin variants
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
KR20030016233A (ko) 2000-02-28 2003-02-26 디코드 제네틱스 이에이치에프 사람 정신분열증 유전자
ATE516304T1 (de) * 2000-05-23 2011-07-15 Cenes Pharmaceuticals Inc Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
AU2001290864A1 (en) 2000-09-12 2002-04-02 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Optimized cardiac contraction through differential phosphorylation of myosin
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
DE10124387A1 (de) * 2001-05-18 2002-11-28 Basf Ag Hydrophob modifizierte Polyethylenimine und Polyvinylamine zur Antiknitterausrüstung von cellulosehaltigen Textilien
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2003293124A1 (en) 2002-11-27 2004-06-23 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
AU2004249114A1 (en) 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition of protein kinase C-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
GB0413005D0 (en) 2004-06-11 2004-07-14 Coletica Ligand
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
CA2590338A1 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
DE602006020853D1 (de) 2006-07-07 2011-05-05 Procter & Gamble Waschmittelzusammensetzungen
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
EP2115477B1 (en) 2007-01-25 2015-06-24 Roche Diagnostics GmbH Use of igfbp-7 in the assessment of heart failure
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2009137837A2 (en) 2008-05-09 2009-11-12 The Regents Of The University Of California Neuregulin/erbb signaling and integrin
PL3338791T3 (pl) 2008-07-17 2020-04-30 Acorda Therapeutics, Inc. Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
US8609620B2 (en) 2008-11-28 2013-12-17 Zensun (Shanghai) Science & Technology Ltd. Neuregulin peptides and their use
WO2010060266A1 (en) * 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin and cardiac stem cells
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
EP2440236B1 (en) 2009-06-09 2016-05-04 Zensun (Shanghai) Science and Technology Limited Neuregulin based methods for treating heart failure
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
PL2544537T3 (pl) * 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
CN103327986B (zh) 2010-07-22 2018-05-25 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法
CN102230084B (zh) * 2011-06-14 2013-01-23 东北大学 低品位含砷难浸金矿的包覆生物氧化预处理方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
HK1206601A1 (en) * 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
RU2650635C2 (ru) * 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2904055A1 (en) 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
US10098834B2 (en) 2013-05-22 2018-10-16 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110840895A (zh) 2013-07-23 2020-02-28 上海泽生科技开发股份有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Also Published As

Publication number Publication date
JP7479068B2 (ja) 2024-05-08
RU2016131667A3 (ru) 2018-08-21
KR20220093387A (ko) 2022-07-05
RU2738158C2 (ru) 2020-12-08
EP3821904B1 (en) 2025-02-05
BR112016015660A2 (pt) 2017-10-24
JP7100083B2 (ja) 2022-07-12
US20170007671A1 (en) 2017-01-12
EP3090756A1 (en) 2016-11-09
KR20160105443A (ko) 2016-09-06
JP2024099628A (ja) 2024-07-25
EP3821904A1 (en) 2021-05-19
EP3090756B2 (en) 2024-09-25
CN111012898A (zh) 2020-04-17
CA2935607A1 (en) 2015-07-09
JP2022130627A (ja) 2022-09-06
JP2017502969A (ja) 2017-01-26
RU2016131667A (ru) 2018-02-08
EP3090756A4 (en) 2017-07-19
US11969458B2 (en) 2024-04-30
US20250073306A1 (en) 2025-03-06
US20210113661A1 (en) 2021-04-22
CN110946993A (zh) 2020-04-03
WO2015101182A1 (zh) 2015-07-09
KR20230054749A (ko) 2023-04-25
CN105960248A (zh) 2016-09-21
JP2020143101A (ja) 2020-09-10
EP3090756B1 (en) 2020-09-30
US10702585B2 (en) 2020-07-07
KR102522140B1 (ko) 2023-04-17
CN104758922A (zh) 2015-07-08
JP6703483B2 (ja) 2020-06-03

Similar Documents

Publication Publication Date Title
AU2014375637A1 (en) Formula of neuregulin preparation
EP3568783A4 (en) MEDICAL ASSISTANT
EP3674314A3 (en) Apelin polypeptides
EP3340935A4 (en) Replacement heart valves and methods of delivery
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IL259711A (en) Methods for the preparation of protein kinase inhibitors and their medical use
EP4599780A3 (en) Matrix implant
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
EP3117802A4 (en) Stent with mechanical or biological heart valve for minimally invasive valve replacement procedure, and applicator
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
PT3110840T (pt) A22k, desb27, b29r, des b30, na posição épsilon de análogo de insulina humana acilada de lisina 22
PT3527552T (pt) Derivado fundido tricíclico de -aminoácido, seu método de preparação, e sua utilização médica
IL257173A (en) New insulin histories and their medical uses
DK3294449T3 (da) Pulverformigt titaniumoxid, fremgangsmåde til fremstilling deraf og anvendelse deraf
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EP3331583B8 (en) Medical implant based on nanocellulose
EP3423021A4 (en) MEDICAL CHAIR
EP3160579A4 (en) Prefitting evaluation of cochlear implant patients
EP3297636A4 (en) Pharmaceutical composition of carboplatin based co-crystals and use thereof
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
MX370540B (es) Combinaciones de amida de ácido 4-[(s) -2-azetidin-1-il-1-(4-cloro -3-trifluorometil - fenil) - etilamino] -quinazolin-8-carboxílico e inhibidores de her2 para usarse en el tratamiento de cáncer.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted